Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia
1Cutler C,Giri S,Jeyapalan S,et al.Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation:a meta-analysis[J].J Clin Oncol,2001,19(16):3685-3691.
2Nemunaitis J.Use of cytokines in the treatment of acute lymphoblastic leukemia[J].Leukemia,1997,11 Suppl 4:S36-37.
3Hicklin D J,Ellis LM.Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis[J].J Clin Oncol,2005,23(5):1011-1027.
4Lee CY,Tien HF,Hu CY,et al.Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia[J].Br J Cancer,2007,97(7):877-882.
5Blum W,Klisovic RB,Becker H,et al.Dose escalation of lenalidomide in relapsed or refractory acute leukemias[J].J Clin Oncol,2010,28(33):4919-4925.
6Fehniger TA,Uy GL,Trinkaus K,et al.A phase 2 study of highdose lenalidomide as initial therapy for older patients with acute myeloid leukemia[J].Blood,2011,117 (6):1828-1833.
7D'Amato R J,Loughran MS,Flynn E,et al.Thalidomide is an inhibitor of angiogenesis[J].Proc Natl Acad Sci U S A,1994,91 (9):4082-4085.
8Richardson P,Hideshima T,Anderson K.Thalidomide:emerging role in cancer medicine[J].Annu Rew Med,2002,53:629-657.
9Davies FE,Raje N,Hideshima T,et al.Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J].Blood,2001,98(1):210-216.
10Guilhot F,Chastang C,Michallet M,et al.Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia.French Chronic Myeloid Leukemia Study Group[J].N Engl J Med,1997,337(4):223-229.
